Eyenovia (NASDAQ:EYEN) Given “Neutral” Rating at HC Wainwright

Eyenovia (NASDAQ:EYEN)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 44.93% from the stock’s previous close.

Eyenovia Price Performance

NASDAQ EYEN opened at $1.38 on Friday. The firm’s fifty day simple moving average is $2.66 and its two-hundred day simple moving average is $17.82. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. Eyenovia has a 12-month low of $1.28 and a 12-month high of $124.80. The firm has a market capitalization of $1.92 million, a P/E ratio of -0.02 and a beta of 1.29.

Institutional Investors Weigh In On Eyenovia

An institutional investor recently raised its position in Eyenovia stock. Geode Capital Management LLC boosted its holdings in shares of Eyenovia, Inc. (NASDAQ:EYEN) by 3.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 577,393 shares of the company’s stock after purchasing an additional 19,399 shares during the period. Geode Capital Management LLC owned about 41.54% of Eyenovia worth $84,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.